Investor's Business Daily on MSN6h
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics
Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug from China's LaNova Medicines.Please watch the video at Investors.com - ...
Wolfe starts Merck at Peer Perform, notes competitive overhangs
Wolfe Research initiated coverage of Merck (MRK) with a Peer Perform rating. The firm said the main sentiment driver for Merck is ...
BioPharma Dive12h
Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy
The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...
Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
FiercePharma1d
BMS, Merck, Amgen and more must look to M&A to offset looming patent lapses: Leerink
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Yahoo Finance9d
Merck Insiders Sold US$11m Of Shares Suggesting Hesitancy
Over the last year, we can see that the biggest insider sale was by the Executive VP & President of Merck Animal Health, Richard DeLuca, for US$4.6m worth of shares, at about US$105 per share.
Top 2 pharma stocks to buy amid surge in deadly fungi
Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...
Reuters29d
Merck's RSV antibody for infants effective in reducing some types of infections in study
Merck had said in July that the shot met the ... buy of Aliada 10:12 PM UTC · Updated ago Future of Healthcategory US FDA approves Iterum's treatment for urinary infection October 25, 2024 ...